ResearchHuman Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
ResearchClinical Characteristics and Survival Outcomes of Metastatic Invasive Lobular and Ductal Carcinoma.
May 2, 2025Journal ArticleCharacterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma.Written by 1 Roon author & 9 others Via Annals of Surgical Oncology
ResearchImmediate and ipsilateral recurrence rates and treatment recommendations for patients with pleomorphic and florid lobular carcinoma in situ.
ResearchLimitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery.
ResearchIncidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study.
ResearchImpact of concurrent lobular carcinoma in situ on recurrence outcomes in patients with classic and pleomorphic invasive lobular carcinoma of the breast.
ResearchEfficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma.
ResearchSummary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-F-Fluoro-17β-Fluoroestradiol.
ResearchSurvival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy.
ResearchAbsence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.
ResearchHistology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies.
ResearchLumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone.